

6. Literaturverzeichnis:

- Adachi W, Koike S, Nimura Y, Koide N, Iida F, Du XQ, Ping YM, He M, Chen LQ, Zhang MD, Zhang HL. Clinicopathologic characteristics and postoperative outcome in Japanese and Chinese patients with thoracic esophageal cancer. *World J Surg* 1996; 20:332-336.
- Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor- γ and levels of prostaglandin E2 and 15-deoxy- $\Delta^{12,14}$ -prostaglandin J2 in human breast cancer and metastasis. *Int J Cancer* 2003; 103: 84-90.
- Bareiss D, Stabenow R, Müller R, Eisinger B, Stegmaier C, Däubler P, Zeitz M, Scherübl H. Aktuelle Epidemiologie des Ösophaguskarzinoms und des Kardiakarzinoms in Deutschland. *Dtsch Med Wochenschr* 2002; 127: 1367-1374.
- Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. *J Natl Cancer Inst* 1993; 85: 1483-92.
- Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications. *Cancer Res* 2003; 63: 1727-1730.
- Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. *Proc Natl Acad Sci USA* 2000; 97: 11280-11285.

- Cardullo RA, Agrawal S, Flores C, Zamecnik PC, Wolf DE. Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer. *Proc Natl Acad Sci USA* 1988; 85: 8790-4.
- Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying non-steroidal antiinflammatory drug-mediated apoptosis. *Proc Natl Acad Sci USA* 1998; 95: 681–686.
- Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, Windsor AC, Guillou PJ, Markham AF, Coletta PL, Hull MA. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. *Am J Pathol* 2000; 156: 545-553.
- Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of *ptgs-1*, as well as *ptgs-2*, reduces intestinal tumorigenesis in min mice. *Cancer Res* 2000; 60: 4705-4708.
- Cooper J, Pajak T, Rubin P, Tupchong L, Brady L, Leibel S, Laramore G, Marcial V, Davis L, Cox J. Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience. *Int J Radiation Oncology Biol Phys* 1989; 17: 449-456.
- Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). *J Histochem Cytochem* 1984; 32: 219-29.

- Corley D, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. *Gastroenterology* 2003; 124: 47-56.
- Crespi M, Munoz N, Grassi A, Qiong S, Jing WK, Jien LJ. Precursor lesions of oesophageal cancer in a low-risk population in China: comparison with high-risk populations. *Int J Cancer* 1984; 34: 599-602.
- Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, Li JY, Blot WJ, Li B, Taylor PR. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. *Cancer* 1994; 74: 1686-1692.
- Dempke W, Rie C, Grothey A, Schmol HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy?. *J Cancer Res Clin Oncol* 2001; 127: 411-417.
- Dobbie Z, Muller PY, Heinimann K, Albrecht C, D'Orazio D, Bendik I, Muller H, Bauerfeind P. Expression of COX-2 and wnt pathway genes in adenomas of familial adenomatous polyposis patients treated with meloxicam. *Anticancer Res* 2002; 22: 2215-2220.
- Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S & DuBois RN. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology* 1994; 107:1183-1188.
- Ell C, May A, Gossner L, Pech O, Günter E, Mayer G, Henrich R, Vieth M, Müller H, Seitz G, Stolte M. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. *Gastroenterology* 2000; 118: 670-677.
- Fagundes R, de Barros S, Putten A, Mello E, Wagner M, Bassi L, Baombassaro M, Gobbi D, Souto E. Occult dysplasia is disclosed by Lugol chromoendoscopy in alcoholics at high risk for squamous cell carcinoma of the esophagus. *Endoscopy* 1999; 31: 325-328.

- Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF, Blot W. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. *Cancer Epidemiol Biomarkers Prev* 1998; 7: 97-102.
- Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, Conti CJ. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. *Mol Carcinog* 1999; 25: 231-240.
- Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. *Cancer* 1995; 76: 1116-1119.
- Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. *Cancer Res* 2000; 60: 2101-2103.
- Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer – a player that's defining the rules. *J Natl Cancer Inst* 2002; 94: 545-546.
- Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Enalp A, Gordon G, Forastiere AA; CBET Research Group. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. *Dis Esophagus* 2003; 16: 177-186.
- Horiuchi M, Makuuchi H, Machimura T, Tamura Y, Sakai M. Survival benefit of screening for early esophageal carcinoma in head and neck cancer patients. *Dig Endosc* 1998; 10: 110-115.
- Hou J, Lin PS, Chen ZF. A study survey of esophagus cancer in Cixian of Hebei. *Chin J Cancer Prev Treat Res* 1998; 25: 73-75.

- Huang M, Sharma S, Mao JT, Dubinett SM. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. *J Immunol* 1996; 157: 5512-5520.
- Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. *Cancer Res* 1998; 58:1208-16.
- Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. *Analyt Biochem* 2000; 278: 175-184.
- Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. *Nat Med* 1999; 5: 1418–1423.
- Kato I, Nomura AM, Stemmermann GN, Chyou PH. Prospective study of the association of alcohol with cancer of the upper aerodigestive tract and other sites. *Cancer: Causes and Control* 1990; 3: 145-151.
- Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in barrett's esophagus. *Gastroenterology* 2002; 123: 60-67.
- Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. *J Oral Pathol Med* 1995; 24: 450-453.

- Krajewska M, Krajewski S, Epstein J, Shabaik A, Sauvageot J, Song K, Kitada S, Reed C. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. *Am J Pathol* 1996; 148: 1567-1576.
- León X, Quer M, Diez S, Orús C, López-Pousa A, Burgués J. Second neoplasms in patients with head and neck cancer. *Head Neck* 1999; 21: 204-210.
- Li H, Yao SC. Surgical treatment for carcinoma of the esophagus in chinese language publications. *Br J Surg* 1997; 84:855-857.
- Leoni-Parvex S, Mihaescu A, Pellanda A, Monnier P, Bosman F. Esophageal cytology in the follow-up of patients with treated upper aerodigestive tract malignancies. *Cancer Cytopathol* 2000; 90: 10-16.
- Lewin KJ, Appelman H. Atlas of tumor pathology. Tumors of the esophagus and stomach. Armed Forces Institute of Pathology, Washington D.C. 1996.
- Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase (COX)-2 is sufficient to induce tumorigenesis in transgenic mice. *J Biol Chem* 2001; 276: 18563-18569.
- Makuuchi H, Machimura T, Shimada H, Mizutani K, Chino O, Kise Y, Nishi T, Tanaka H, Mitomi T, Horiuchi M, Sakai M, Gotoh J, Sasaki J, Osamura Y. Endoscopic screening for esophageal cancer in 788 patients with head and neck cancers. *Tokai Exp Clin Med* 1996; 21: 139-145.
- Mandard AM, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. *Mutation Research* 2000; 462: 335-342.
- Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. *Cancer Res* 1992; 52: 5575-5589.

- Matsumoto K, Okazaki H, Nakamura T. Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. *J Biochem (Tokyo)* 1995; 117:458–464.
- Mellow MH, Layne EA, Lipman TO, Kaushik M, Hostetler C, Smith JC Jr. Plasma zinc and vitamin A in human squamous carcinoma of the esophagus. *Cancer* 1983; 51:1615-1620.
- Munoz N, Crespi M, Grassi A, Qing WG, Qiong S, Cai LZ. Precursor lesions of oesophageal cancer in high-risk populations in Iran and China. *Lancet* 1982; 1: 876-879.
- Muto M, Hironika S, Natanabe M, Boku N, Ohtsu A, Yoshida S. Association of multiple lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. *Gastrointest Endosc* 2002; 56: 517-521.
- Muto M, Nakane M, Hitomi Y, Yoshida S, Sasaki S, Ohtsu A, Yoshida S, Ebihara S, Esumi H. Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer. *Carcinogenesis* 2002; 23: 1759-65.
- Neufang G, Furstenberger G, Heidt M, Marks F, Muller-Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. *Proc Natl Acad Sci USA* 2001; 98: 7629-7634.
- Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in APC Δ 716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2). *Cell* 1996; 87: 803-809.
- Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. *Int J Cancer* 1993; 54: 594-606.

- Petit T, Georges C, Jung G, Borel C, Bronner G, Flesch H, Massard G, Velten M, Haegele P, Schraub S. Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. *Ann Oncology* 2001; 88: 701-705.
- Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. *BJU Int.* 2004; 93: 275-278.
- Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. *Biochem Pharmacol* 2002; 63: 343-347.
- Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. *Science* 1985; 20: 1350-1354.
- Savary J, Grosjean P, Monnier P, Fontollet C, Wagnieres G, Braichotte D, van den Bergh H. Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases. *Endoscopy* 1998; 30: 258-265.
- Scherübl H, von Lampe B, Faiss S, Däubler P, Bohlmann P, Plath T, Foss HD, Scherer H, Strunz A, Hoffmeister B, Stein H, Zeitz M, Riecken EO. Screening for esophageal neoplasia in patients with head and neck cancer. *Br J Cancer* 2002; 86: 239-243.
- Scherübl H, Scherer H, Hoffmeister B. Second esophageal cancers in head and neck cancer patients. *N Engl J Med* 2002; 346: 1416-1417.
- Scherübl H, Sutter A, Zeitz M. NSAIDs and esophageal cancer. *Gastroenterology* 2003; 125: 1914-1915.

- Scherübl H, Zeitz M. Esophageal cancer. *N Engl J Med* 2004; 350: 1363-1364.
- Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. *Gut* 2000; 47: 251-255.
- Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and bcl-2-expression by prostaglandin E2 in human colon cancer cells. *Cancer Res* 1998; 58: 362-366.
- Shibuya H, Wakita T, Nakagawa T, Fukuda H, Yasumoto M. The relation between an esophageal cancer and associated cancers in adjacent organs. *Cancer* 1995; 76: 101-105.
- Shiozaki H, Tahara H, Kobayashi K, Yano H, Tamura S, Imamoto H, Yano T, Oku K, Miyata M, Nishiyama K "Endoscopic screening of early oesophageal cancer with the Lugol dye method in patients with head and neck cancer. *Cancer* 1990; 66: 2068-2071.
- Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. *Gastroenterology* 2000; 118: 487-96.
- Sinicropo FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. *Gastroenterology* 1999; 117: 350-358.

- Slaughter DP, Southwick HW, Smejkal W. "Field cancerization" in oral stratified squamous epithelium. *Cancer (Phila.)* 1953; 6: 963–968.
- Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. *Annu Rev Biochem* 2000; 69: 145-182.
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 2000; 342: 1946-1952.
- Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. *Trends Pharmacol Sci* 2003; 24: 96-102
- Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. *FASEB J* 2001; 15: 2057-2072.
- Thun MJ. NSAIDs and esophageal cancer: ready for trials but not yet broad clinical application. *Gastroenterology* 2003; 124: 246-248.
- Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. *Cancer Res* 2002; 62: 3395-3401.
- Tsuji M, Dubois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell* 1995; 83: 493-501.
- Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. *Clin Cancer Res* 2000; 6: 135-138.
- Valsecchi M. Modelling the relative risk of esophageal cancer in a case-control study. *Clinical Epidemiology* 1992; 45: 347-355.

- Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol* 1998; 38: 97-120.
- Wu MT, Wu DC, Hsu HK, Kao EL, Lee JM. Relationship between site of esophageal cancer and areca chewing and smoking in Taiwan. *Br J Cancer* 2003; 89: 1202-1204.
- Yuan A, Yu CJ, Luh KT, Chen WJ, Lin FY, Kuo SH, Yang PC. Quantification of VEGF mRNA Expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR. *Lab Invest* 2000; 80: 1671-1680.
- Yokoyama A, Omori T. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. *Jpn J Clin Oncol* 2003; 33: 111-121.
- Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. *Cancer Res* 1999; 59: 198-204.